CompletedPhase 4

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Type 2-diabetic Patients Using Exendin [9-39] as a GLP-1 Receptor Antagonist

Lead sponsor

Diabeteszentrum Bad Lauterberg im Harz

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•BMI 20-35•HbA1c 6.5-9%•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02639130

Org study IDDZBL-2007-1

Timeline

Milestones

Study first posted2015-12-24estimated

Last update posted2016-08-16estimated

Study start2008-02 (month precision)

Primary completion2010-01actual (month precision)

Study completion2010-01actual (month precision)

Assets

Investigational agents

Avexitide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age30 Years

Maximum age75 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Treatment with either diet/exercise or metformin

•HbA1c 6.5 - 9.0 %

•Fasting plasma glucose 6.0 - 11.0 mmol/l

•Body-mass-index 20.0 - 35.0 kg/m²

•Healthy controls were required to have a normal oral glucose tolerance test (75g) and no first-degree relatives with type 2 diabetes nor a personal history of gestational diabetes

Exclusion criteria

•Significant heart, kidney (serum creatinine ≤ 123 µmol/l in woman and ≤ 132 µmol/l in men), liver (transaminases < 2fold upper limit of normal) and gastrointestinal disease

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.